Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

Tonyali, Onder; Coskun, UĞUR; Sener, Nur; İNANÇ, MEVLÜDE; Akman, Tulay; Oksuzoglu, Berna; Ozdemir, Nuriye; Yazilitas, Dogan; Benekli, Mustafa; ÜNER, AYTUĞ; Yamac, Deniz; Demirci, Umut; Yildiz, Ramazan; Karaca, Halit; Unal, Olcun; Bal, Oznur; Gumus, Mahmut; Buyukberber, Suleyman

doi:10.1007/s00432-012-1296-x

Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

Atıf İçin Kopyala

Tonyali O., Coskun U., Sener N., İNANÇ M., Akman T., Oksuzoglu B., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.138, sa.12, ss.2145-2151, 2012 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 138 Sayı: 12
Basım Tarihi: 2012
Doi Numarası: 10.1007/s00432-012-1296-x
Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2145-2151
Anahtar Kelimeler: Trastuzumab, Adjuvant therapy, Breast cancer, HER2, PLUS ADJUVANT CHEMOTHERAPY, DOCETAXEL, ONCOGENE
Gazi Üniversitesi Adresli: Evet

Özet

Purposes Trastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the efficacy and toxicity of 9- and 52-week trastuzumab therapy for EBC retrospectively.